Cargando…

Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET

Ovarian cancer is one of the most aggressive female reproductive tract tumors. Paclitaxel (PTX) is widely used for the treatment of ovarian cancer. However, ovarian cancers often acquire chemotherapeutic resistance to this agent. We investigated the mechanism of chemoresistance by analysis of microR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitamura, T, Watari, H, Wang, L, Kanno, H, Hassan, M K, Miyazaki, M, Katoh, Y, Kimura, T, Tanino, M, Nishihara, H, Tanaka, S, Sakuragi, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641356/ https://www.ncbi.nlm.nih.gov/pubmed/23552883 http://dx.doi.org/10.1038/oncsis.2013.3

Ejemplares similares

microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway
por: Mitamura, Takashi, et al.
Publicado: (2014)

Correction: microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway
por: Mitamura, Takashi, et al.
Publicado: (2014)

P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane
por: Hassan, Mohamed Kamel, et al.
Publicado: (2015)

miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2
por: Mohamed, Zeinab, et al.
Publicado: (2018)

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
por: Hassan, Mohamed K, et al.
Publicado: (2011)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments
por: Mitamura, Takashi, et al.
Publicado: (2014)

Adaptor protein CRK induces epithelial–mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop
por: Matsumoto, Ryuji, et al.
Publicado: (2015)

Prognostic Implication of Histological Oligodendroglial Tumor Component: Clinicopathological Analysis of 111 Cases of Malignant Gliomas
por: Kanno, Hiromi, et al.
Publicado: (2012)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation
por: Marona, Paulina, et al.
Publicado: (2022)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer
por: Chen, Danni, et al.
Publicado: (2020)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

A Clinicopathological Analysis of Six Autopsy Cases of Sudden Unexpected Death due to Infectious Aortitis in Patients with Aortic Tears
por: Ishikawa, Marin, et al.
Publicado: (2018)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy
por: Kato, Tatsuya, et al.
Publicado: (2013)

Oncological Outcomes After Okabayashi-Kobayashi Radical Hysterectomy for Early and Locally Advanced Cervical Cancer
por: Sakuragi, Noriaki, et al.
Publicado: (2020)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Optimal use of taxanes in metastatic breast cancer
por: King, K.M., et al.
Publicado: (2009)

Taxane-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2015)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

Downregulation of the tyrosine degradation pathway extends Drosophila lifespan
por: Parkhitko, Andrey A, et al.
Publicado: (2020)

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer
por: Steg, Adam D., et al.
Publicado: (2014)

miRNAs from Inflamed Gingiva Link Gene Signaling to Increased MET Expression
por: Zheng, L., et al.
Publicado: (2023)

Multivariate survival analysis of the patients with recurrent endometrial cancer
por: Odagiri, Tetsuji, et al.
Publicado: (2011)

Membrane dynamics of resting and internalin B‐bound MET receptor tyrosine kinase studied by single‐molecule tracking
por: Harwardt, Marie‐Lena I. E., et al.
Publicado: (2017)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

The taxanes: toxicity and quality of life considerations in advanced ovarian cancer
por: Guastalla III, J P, et al.
Publicado: (2003)

Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study
por: Zhai, Tianyue, et al.
Publicado: (2023)

An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
por: Altintas, D. M., et al.
Publicado: (2023)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p1lrp4v1c9g5cijlg5rcb1boa3